No Data
Zhejiang Shengda Bio-Pharm (603079.SH) has successfully passed the Shanghai Stock Exchange's review for the issuance of stocks to specific individuals.
Zhejiang Shengda Bio-Pharm (603079.SH) announced that the company recently received a notice from the Shanghai Stock Exchange listing review center "...
zhejiang shengda bio-pharm (603079.SH): folic acid raw materials are all purchased externally
Grain alliance November 22nd, zhejiang shengda bio-pharm (603079.SH) stated on the investor interaction platform that folic acid is one of our main products, and the raw materials of folic acid are all purchased externally.
Guosheng Securities: Sufficient folic acid inventory has been cleared, and the turning point has appeared. The industry structure continues to be concentrated.
Benefiting from the growth of high-value-added human demand, the global demand for folic acid reached 2,100 tons in 2023, of which domestic demand increased from 310 tons in 2019 to 600 tons, with a compound growth rate of 17.95%.
Subdued Growth No Barrier To Zhejiang Shengda Bio-Pharm Co., Ltd. (SHSE:603079) With Shares Advancing 28%
Zhejiang Shengda Biopharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Zhejiang Shengda Biopharmaceutical Co., Ltd. announced the main operating data for the third quarter of 2024
Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) Shares Bounce 26% But Its Business Still Trails The Industry
